Q4 2022 Results slide image

Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Cardiovascular Oncology Appendix Abbreviations Other 60 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation